

Resource Summary Report

Generated by NIF on Sep 2, 2026

National Psoriasis Foundation

RRID:SCR_004454

Type: Tool

Proper Citation

National Psoriasis Foundation (RRID:SCR_004454)

Resource Information

URL: <http://www.psoriasis.org/>

Proper Citation: National Psoriasis Foundation (RRID:SCR_004454)

Description: The National Psoriasis Foundation (NPF) is a non-profit, voluntary health agency dedicated to finding a cure for psoriasis and psoriatic arthritis and eliminating their devastating effects through research, advocacy and education. Founded in 1966, the Psoriasis Foundation has evolved to become the leading patient advocacy group for the 7.5 million Americans living with psoriasis and psoriatic arthritis. As emerging research continues to demonstrate the serious, systemic effects of these chronic autoimmune diseases, our highest priority is to find a cure. Guided by our five year-strategic plan, we are moving towards this goal with an integrated approach that leverages the work of members, health care providers, advocates and scientists in four critical areas: * Research: ** Directly supporting the most promising early-stage research and emerging researchers. ** Hosting the world's largest bank of psoriasis DNA samples. * Advocacy: ** Advancing a public policy agenda to secure more federal funding for psoriasis research. ** Improving access to care for patients. * Education: ** Providing extensive patient education. ** Keeping health care professionals up to date on psoriasis treatment. * Connection: ** Online communities, support networks, mentorship programs. ** Building a grassroots network of volunteers and advocates. * Leadership: ** A volunteer Board of Trustees steers the strategic direction of the National Psoriasis Foundation. ** Our Medical Board, made up of leading national psoriasis experts, provides medical guidance, leadership and advocacy. ** An executive staff of seasoned non-profit leaders drives the organization to achieve its strategic plan goals.

Abbreviations: NPF

Synonyms: Psoriasis Foundation

Resource Type: institution

Funding: individual donors ;
private foundations ;

corporate partners

Resource Name: National Psoriasis Foundation

Resource ID: SCR_004454

Alternate IDs: ISNI: 0000 0004 4904 0118, Crossref funder ID: 100003185, nlx_44871, Wikidata: Q6975105, grid.453839.0

Alternate URLs: <https://ror.org/005gjff63>

Record Creation Time: 20220129T080224+0000

Record Last Update: 20260829T182154+0000

Ratings and Alerts

No rating or validation information has been found for National Psoriasis Foundation.

No alerts have been found for National Psoriasis Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Akshatha CR, et al. (2026) Cancer Related Fatigue and its Association with Depression and Anxiety in the Patients with Advanced Gastric Cancer. Journal of gastrointestinal cancer, 57(1).

Sakarkar S, et al. (2025) Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne. Molecules (Basel, Switzerland), 30(12).

Hughes AN, et al. (2024) Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica. JID innovations : skin science from molecules to population health, 4(6), 100296.

Daudén E, et al. (2024) Defining well-being in psoriasis: A Delphi consensus among healthcare professionals and patients. Scientific reports, 14(1), 14519.

Sarkar R, et al. (2016) General measures and quality of life issues in psoriasis. Indian dermatology online journal, 7(6), 481.

Aldredge LM, et al. (2016) Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant. Journal of the Dermatology Nurses' Association, 8(1), 14.

Sundarrajan S, et al. (2015) Insights into protein interaction networks reveal non-receptor kinases as significant druggable targets for psoriasis. *Gene*, 566(2), 138.

Clop A, et al. (2013) An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. *PloS one*, 8(8), e71690.

Lewis-Beck C, et al. (2013) Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. *Patient preference and adherence*, 7, 199.

Dalmády S, et al. (2013) Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris. *Clinical & developmental immunology*, 2013, 474028.

Liu Y, et al. (2012) NF- κ B repression by PIAS3 mediated RelA SUMOylation. *PloS one*, 7(5), e37636.